ClinicalTrials.gg
CompletedNCT00591331Updated May 20, 2008

Phototoxicity Potential of NatrOVA Creme Rinse - 1%

A Phase 1 interventional study of Spinosad (the active ingredient in NatrOVA) and placebo in Head Lice, sponsored by ParaPRO LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-05-20.

Sponsored by ParaPRO LLC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the primary irritation potential of NatrOVA Creme Rinse - 1% in humans, after exposure to UV radiation.

02

Conditions studied

  • Head Lice

Keywords

  • Head Lice
03

In context

Lead sponsor

ParaPRO LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 18-65 years of age and in good health.
  2. Fitzpatrick skin type I, II or III

Exclusion criteria

Exclusion Criteria:

  1. History of severe reactions from exposure to sunlight
  2. Known allergies or sensitivities to adhesives in patches
  3. Inability to evaluate the skin in and around the test sites
  4. Diabetes requiring medication
  5. Clinical significant skin disease
  6. Asthma or other severe respiratory disease
  7. Known immunological disorders such as , AIDS, lupus,rheumatoid arthritis
  8. History or current skin cancer
  9. Mastectomy for cancer involving removal of lymph nodes draining the test sites
  10. Epilepsy
  11. Pregnancy, lactation, or planned pregnancy during study period
  12. Chronic use of systemic antihistamine medication within 14 days of screening
  13. Use of anti-inflammatory drugs within 2 days of Screening Visit 1
  14. Currently receiving allergy injections
  15. Use of drugs
  16. Topical drugs used at the test site within 7 days of Screening Visit 1
  17. Current participation in any clinical trial
  18. Participation in any patch test for irritation or sensitization or UV exposures within 4 weeks of study start
  19. Use of any drug therapy within 4 weeks of study start.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    1

    NatrOVA Creme Rinse - 1%

    Drug: Spinosad (the active ingredient in NatrOVA)

  • Experimental
    2

    NatrOVA Creme Rinse Vehicle Only

    Drug: Spinosad (the active ingredient in NatrOVA)

  • Placebo comparator
    3

    Blank patch

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety endpoint will be visual grading of UV irradiated test sites and assessments of adverse experiences

    Time frame: 7 days

07

Study locations

1 site
  • Hill Top Research
    St. Petersburg, Florida 33710, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2007
First posted
Jan 11, 2008
Start
Dec 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
May 20, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00591331
Lead sponsor
ParaPRO LLC
First posted
Jan 11, 2008
Start date
Dec 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
May 20, 2008

Study contacts

John V Murray, MD
principal investigator · Hill Top Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spinosad

Start the discussion